Quantcast

Latest Tardive dyskinesia Stories

370572c9a414d9bd74461f1845d6423a1
2009-02-27 11:12:08

The US Food and Drug Administration is requiring makers of the heartburn drug Reglan to add a "black box" warning to inform patients that long term or high doses of the drug have been linked to involuntary movement throughout the body. More than 2 million Americans use the drugs to treat gastroesophageal reflux disease and other stomach problems, said the FDA. However, they warn that chronic use can cause tardive dyskinesia "“ characterized by uncontrollable repetitive movements of the...

2009-02-26 14:42:32

The U.S. Food and Drug Administration is ordering manufacturers of the drug metoclopramide to add a boxed warning about the drug's side effects. The FDA said the drug, used to treat gastrointestinal disorders, is sold as tablets, syrups and injections as Reglan Tablets, Reglan Oral Disintegrating Tablets, Metoclopramide Oral Solution and Reglan Injection. The federal agency said more than two million U.S. residents use the products. FDA officials said the boxed warning must be added to the...

2009-01-15 05:05:00

INDIANAPOLIS, Jan. 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has reached resolution with the United States Attorney for the Eastern District of Pennsylvania (EDPA) and the Office of Consumer Litigation of the Department of Justice regarding the previously-reported government investigation into the company's past U.S. marketing and promotional practices for the antipsychotic medication Zyprexa(R) (olanzapine). Lilly has been cooperating...

2009-01-13 13:01:00

DURHAM, N.C., Jan. 13 /PRNewswire/ -- S&R Communications Group has entered a strategic partnership with Ovation Pharmaceuticals, Inc., to launch Xenazine* (tetrabenazine), a treatment for chorea associated with Huntington's disease (HD). Xenazine is the first and only FDA-approved treatment specifically developed for any HD-related symptom. "In recent months, the S&R team worked tirelessly to help Ovation launch Xenazine," said S&R President Paul Dreyer. "Having been...

2009-01-07 17:12:00

INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults. Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of the NDA. Per the agency's...

2008-10-28 06:00:28

By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979. Over the years, he estimates, he has dispensed tetrabenazine -- or TBZ, as he calls it -- to 1,000 people with Huntington's disease, probably more than any doctor in the world. Tetrabenazine helps tame the uncontrollable movements, or "chorea," that characterize Huntington's, an inherited...

2008-09-26 06:00:12

INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long-acting Injection (LAI), known in Europe by the trade name Zypadhera(TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today. The CHMP's positive opinion is now referred for final action to the European...

2008-09-17 09:00:14

OVATION Pharmaceuticals, Inc. announced today that it has acquired from Prestwick Pharmaceuticals the exclusive license in the United States to commercialize Xenazine(R) (tetrabenazine), an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's Disease (HD). Financial terms of the deal were not disclosed. Subsequently, Biovail Corporation, Canada's largest publicly traded pharmaceutical company, acquired Prestwick....

2008-08-18 12:00:56

Prestwick Pharmaceuticals has announced that the FDA has approved Xenazine for the treatment of chorea associated with Huntington's disease. Xenazine is said to be the first and only FDA-approved treatment for any symptom of Huntington's disease (HD) and is expected to be available later 2008. A double-blind, placebo-controlled, Phase III study found that Xenazine significantly reduced patients's chorea burden, improved global outcome scores, and was generally safe and well tolerated....

891e7e55db7a0b85faf798c8b9fbf9411
2008-08-18 12:05:00

The U.S. Food and Drug Administration announced approval of Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington's disease. The FDA said Xenazine is a new drug and the first treatment of any kind approved in the United States for any symptom of Huntington's disease. Currently there are no other drugs that are FDA-approved to treat chorea -- the jerky, involuntary movement that occurs in people with the disease. The federal agency said side effects reported with use...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin